A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil
- Registration Number
- NCT00672945
- Lead Sponsor
- Epix Pharmaceuticals, Inc.
- Brief Summary
A randomized placebo-controlled study to evaluate the efficacy of PRX-03140 in subjects with Alzheimer's Disease receiving a stable dose of donepezil. The study consists of a 26-week double-blind treatment period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 420
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description PRX-03140 PRX-03140 - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Alzheimer's Disease Assessment Scale-Cognitive subscale.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (38)
Barrow Neurological Institute
🇺🇸Phoenix, Arizona, United States
PsyPharma Clinical Research, Inc.
🇺🇸Phoenix, Arizona, United States
Northwest NeuroSpecialists, PLLC
🇺🇸Tucson, Arizona, United States
Synergy Clinical Research Center
🇺🇸National City, California, United States
Pacific Neuroscience Medical Group
🇺🇸Oxnard, California, United States
California Neuroscience Research Medical Group, Inc.
🇺🇸Sherman Oaks, California, United States
Torrance Clinical Research
🇺🇸Torrance, California, United States
Bradenton Research Center
🇺🇸Bradenton, Florida, United States
Brain Matters Research
🇺🇸Delray Beach, Florida, United States
Clinical Neuroscience Solutions, Inc.
🇺🇸Jacksonville, Florida, United States
Scroll for more (28 remaining)Barrow Neurological Institute🇺🇸Phoenix, Arizona, United States